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Background: Aspirin – exacerbated respiratory disease can prove difficult to control. Oral aspirin desensitization is
effective, but has adverse effects and may not be cardio-protective at the high doses needed.
Objective: To examine the effectiveness of aspirin administered in lower doses via the nose.
Methods: An audit of 121 patients with aspirin exacerbated respiratory disease (AERD), 105 of whom were treated
with intranasal lysine aspirin in gradually increasing doses following positive lysine aspirin challenge.
Results: Treatment was associated with subjective symptomatic improvement or stabilization in 60 of 78 patients at
3 months and 19 of 27 at 12 months. Nasal inspiratory peak flow, olfaction, exhaled and nasal nitric oxide levels
were significantly improved (p < 0.05 for all). Patients with positive skin prick tests and those with later onset
(>40 years) AERD improved more than non-atopics and those with early onset AERD.
Asthma outcomes over 1 year were assessed by questionnaire in 22 patients on lysine aspirin and in 20 who were
positive on challenge but who either refused treatment or took it only briefly (less than or equal to 3 months).
There was a significant decrease in emergency visits (p = 0.0182), hospitalization (p = 0.0074) and oral steroid use
(p = 0.004) in those on nasal lysine aspirin for a year.
Gastrointestinal side effects occurred in 3.8%, lower than those reported for oral aspirin therapy. Conclusions and
Clinical Relevance This form of therapy might reduce the need for expensive monoclonal antibodies in AERD
patients.
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Aspirin-exacerbated respiratory disease (AERD) is a
difficult-to-treat chronic inflammatory disease charac-
terised by asthma, chronic rhinosinusitis with nasal polyp-
osis and sensitivity to aspirin and other cyclo-oxygenase 1
(COX-1) inhibiting non-steroidal anti-inflammatory drugs
(NSAIDs) [1].
Patients with AERD have been shown to have high levels
of pro-inflammatory molecules [2] and low levels of anti-
inflammatory ones [3], leading to damage of the respira-
tory mucosa [4], with resulting aggressive nasal polyposis
and eosinophilic asthma [5].
Ingestion of aspirin or COX-1 NSAIDs inhibit cyclo-
oxygenase 1 leading to increased availability of substrate
for the lipoxygenase enzymes that produce leukotrienes,* Correspondence: g.scadding@ucl.ac.uk
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unless otherwise stated.further increasing pro-inflammatory mediators and redu-
cing protective prostaglandin E2. Acute hypersensitivity
reactions can occur, leading to sudden onset broncho-
spasm, rhinitis, laryngospasm or even death [5].
Many AERD patients are refractory to standard medical
therapy, undergo numerous surgical polypectomies and re-
quire frequent oral corticosteroids for asthma [6]. Multiple
open studies show oral desensitization and daily aspirin
treatment can significantly improve overall symptoms and
quality of life, decrease nasal polyp formation and sinusitis,
reduce the need for oral corticosteroids and sinus surgery
and improve nasal and asthma scores in patient with
AERD at 6 months and after one year of therapy [7]. How-
ever maintenance treatment with oral aspirin should be at
least 300 mg daily, ideally 325 mg twice a day [7,8], a dose
associated with gastro-intestinal or other complications in
14% of patients [9]. Oral doses of aspirin over 100 mg havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sibly detrimental to the cardiovascular system [10].
Lysine acetyl-salicylate (LAS) (Synthelabo, Paris) ,the
only truly soluble form of aspirin, is less likely to damage
respiratory and gastric mucosae. Direct application of
LAS onto involved polyp tissue means that a higher in-
tranasal concentration can be achieved without exposing
the gut or the heart to high doses. This is an open audit
of the effects of topical nasal LAS on the upper and
lower respiratory tract in patients with refractory AERD.
Materials and Methods
121 patients (61 men and 60 women; mean age ± standard
deviation (SD), 45.6 ± 12.6 years) with aspirin-exacerbated
respiratory disease were recruited from the Rhinology
Clinic at the Royal National Throat, Nose and Ear Hos-
pital, London. All were refractory to standard medical
therapy with nasal douche and intranasal corticosteroids,
plus inhaled corticosteroids, β-agonists, combinations of
inhaled corticosteroid plus long acting beta β-agonists and
anti-leukotrienes (LTRAs). They had undergone a mean of
3.3 sinus operations. All gave written informed consent to
lysine aspirin nasal challenge and verbal consent to con-
tinuation of lysine aspirin therapy at home after a positive
challenge. Aspirin-sensitivity was suspected based on the
patients’ histories and confirmed by nasal challenge with
lysine-aspirin, as previously described [11]. This involves
initial symptom scores and nasal airway measurements
followed by a graduated nasal challenges with saline,
followed by increasing doses of lysine aspirin starting with
5 mg aspirin equivalent ,then 10 mg, 20, 40, at 45 minute
intervals, until either the patient has responded with nasal
symptoms plus a 25% decrease in the nasal airway or a cu-
mulative dose of 75 mg aspirin has been reached without
any reaction. In that case oral challenge with 100 mg, then
200 mg was given. The exception was 3 patients with a
convincing double positive history of previous reactions to
both aspirin and another COX-1 inhibitor who did not re-
quire formal challenge [11].
Patients who consented to nasal therapy with LAS
continued to take their usual medical therapy.
The project (reference 06/Q0301/6) was approved by
East of England NRES Research Ethics committee.
Dosing with lysine aspirin
Treatment was started at home on the day after the LAS
nasal challenge using drops (50 ul each) from a freshly pre-
pared 50 mg/ml solution of LAS in sodium chloride 0.9%.
Written instructions for use were given to the patient to-
gether with lysine aspirin sachets, a bottle, a dropper and a
24 hour mobile number for advice. The starting dose for
therapy was the dose to which the patient had responded
intra-nasally on the previous day plus an extra one drop
into each nostril. The patient was given instructions toincrease similarly the number of drops each day, up to
a maximum of nine drops in each nostril, equivalent to
45 mg of aspirin, until assessment at 3 months. The
number of drops was further increased each day up to
a maximum of 15–20 drops in each nostril equivalent
to 75–100 mg aspirin.
Patients were warned that if they missed more than
one day’s therapy they should not re- start at home, but
should return to the hospital.
Exclusion criteria included pregnancy, a history of an im-
mediate anaphylactic or urticarial reaction to aspirin or
NSAID, bleeding diatheses, severe gastro-intestinal disease or
patients considered unable to use such medication regularly.
The following parameters were assessed before intranasal
administration: symptoms of asthma, rhinitis and nasal
polyps on a visual analogue scale, nitric oxide levels in
upper (nNO) and lower (e NO) airway, nasal inspiratory
peak flow, smell and spirometry. Following at least 3 months
of treatment, each patient was re-assessed, this was re-
peated at 12 months.
Sub-group analysis was performed to determine the
phenotype of those who responded well to LAS treat-
ment. Potential factors considered were:
 Anti-leukotriene response (benefit, no benefit) [12]
 Age of AERD onset (<40 y, >40 y)
 Skin prick tests (positive, negative)
Subjective evaluation
Each patient evaluated global treatment effectiveness
based on whether their symptoms had improved, wors-
ened or not changed. They also assessed their current
symptoms of asthma, rhinitis (nasal itch, running, sneez-
ing) and nasal polyps (nasal obstruction, sense of smell),
using a validated visual analogue scale [13].
Objective evaluation
Recommended measures for polyp assessment including
nasal airway measurement (nasal inspiratory peak flow),
nasal nitric oxide and olfactory ability were used [14].
Not all patients had all measurements taken at every
visit because of lack of time or staff.
Nasal inspiratory peak flow(NIPF)
Nasal inspiratory peak flow was assessed as previously
described [15], using a nasal inspiratory peak flow meter,
with the best of three values being recorded.
Nitric oxide
Nitric oxide levels were assessed by chemiluminescence
using the Logan-Sinclair analyser (Logan Research,
Rochester, UK). Values were taken from both sides of
the nose and the lower respiratory tract, according to
European guidelines [16].
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The ability to smell was scored using Le Nez du Vin system
[17], with a maximum score of 6.
Spirometry
Lower respiratory function was evaluated using a spir-
ometer (Model Vitalograph 2160, Maids Moreton, UK),
complying with the European Respiratory Society Rec-
ommendations [18]. The forced vital capacity, FVC (%
predicted), forced expiratory volume in 1 second, FEV1
(% predicted) and FEV1/FVC(%) were recorded.
Asthma outcomes
Asthma outcomes were evaluated by means of a question-
naire (see questionnaire at Appendix) sent to patients who
had received 1 or more years of LAS therapy and to those
who had a positive challenge but had not taken LAS or
had received 3 months treatment or less.
Statistical analysis
The student t-test was used to analyse the paired data
using Stata 11.2. P values of less than 0.05 were classed
as significant. Data, where applicable, are expressed as
mean ± standard error of the mean.
Results
Patients
Figure 1 shows a flow diagram for the patients in this
audit. Sixteen patients declined LAS treatment despite a
positive challenge. Of the 105 who started treatment, three
had positive histories of both aspirin and NSAID sensitiv-
ity and did not require formal LAS challenge [11] so were
started on 10 mg intra-nasally.
Nasal symptoms occurred on the second and subsequent
doses of lysine aspirin in over 95% of patients, but were less
severe than those experienced after initial challenge. In
most these completely abated within days to several weeks.
Twenty five patients dropped out within 3 months, 8
within two weeks: the reasons being severe worsening of
nasal symptoms- (n = 8) inability to maintain the daily
regimen (n = 5) and abdominal pains (n = 2), ten patients
did not return for their 3 month visit.
Treatment was stopped at the 3 month assessment in 24
patients, due to a variety of reasons including upper re-
spiratory tract infection or acute sinusitis (n = 2), exacer-
bation of symptoms, particularly those of asthma (n = 2),
worsening of nasal obstruction (n = 3), lack of concord-
ance (n = 2) or lack of efficacy (n = 15).
Twenty drop outs between 3 and 12 months related to
lack of efficacy or difficulty with the regime, 9 subjects
were lost to follow up.
At 12 months treatment was stopped in 2 patients, one
because of gastrointestinal symptoms, the other lack
of efficacy.Patients who stopped and re-started LAS treatment
were excluded from the 12 month analysis, leaving 27
for assessment.
Final doses reached
Most subjects reached 75 mg intra-nasally and continued
on this dose. Two individuals were unable to increase the
dose further than 9 drops in each nostril (=45 mg) because
of worsening asthma at higher doses, but continued with
9 drops each side.
GastrointestinalSide-effects
Four patients (3.8%) experienced gastrointestinal (GI)
side-effects: two patients within the first couple of weeks;
one each at 3 and 12 months.
Subjective Evaluation
Table 1 shows the percentage of patients who reported
improvement, worsening or no change in their symp-
toms at 3 months and 12 months.
Objective Measurements
Significant improvements were seen in NIPF at 3 months
compared to pre-treatment values (145.4 ± 8.7 l/min pre-
treatment and 163.3 ± 8.51 l/min at 3 months, p < 0.05),
this increase was sustained at 12 months (Table 2).
There were improvements in nasal nitric oxide (nNO)
levels in both sides of the nose at 3 and 12 months, p < 0.05
for all.
Significant changes were seen in the lower respiratory
tract nitric oxide levels: at 3 months there was an in-
crease in expired nitric oxide (eNO), but at 12 months it
was significantly lower (16.3 ± 3.6 ppb pre-treatment and
7.5 ± 0.8 ppb at 12 months, p < 0.05). This reduction in
eNO remains the case in patients now treated for two or
more years.
There was a significant increase in the Nez du Vin smell
scores at both 3 and 12 months (p < 0.05 at 3, p < 0.01 at
12 months).
Lung function measurements were not significantly
affected at any time point.
Asthma control
Data was obtained for 22 treated and 20 un-or-briefly
treated patients. In the former none needed emergency
or hospital asthma treatment and 4 required a course of
oral prednisolone. In those who had discontinued treat-
ment, 6 had extra primary care visits for asthma, 5
attended a hospital emergency department, 6 were hos-
pitalized with asthma exacerbations and 13 had prednis-
olone courses. These figures are highly significantly in
favour of lysine aspirin nasal therapy: p = 0.019, 0.007,
0.004 respectively.
Did not start treatment e.g. 
refused treatment, unable to 
start due to other 
commitments (n=16) 
Continued LAS treatment (n=56) 
Stopped at 12 month assessment (n=23) 
Dropouts 3-12 months (n=20) 
Continued LAS treatment (n=25) 
Started LAS treatment (n=105, including 3 
started based on history alone) 
) 
9
12 month assessment (n=27) 
Stopped at 3 month assessment (n=24) 
Early dropouts (<3 months ) (n=25) 
3 month assessment (n=80) 
History of very severe 
reaction so did not want  
challenge (n=9) 
LAS challenge not done (n=12) previous asthma 
attacks following both aspirin and NSAID 
exposure in 3 
Positive LAS 
challenge (n=118) 
Figure 1 Flow diagram of patients included in audit.
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negative patients
NIPF increased at 3 m compared to pre-treatment in
those with positive SPT (143.6 ± 10.3 L/min pre- and
170.8 ± 8.1 at 3 months, p < 0.01), but not for those
whose SPT were negative (152.3 ± 16.1 L/min pre- and
151.5 ± 18.7 L/min at 3 months, p = 0.48).
Smell test score improved at 3 m and 12 m compared
to pre-treatment in those who had positive SPT (p < 0.01
at 3 m and p < 0.05 at 12 m), but not for those whose
SPT were negative (p = 0.29 and p = 0.19 respectively).
Subjective evaluation scores for asthma in those with
positive SPT tended to be better than those who had
negative SPT with 83% and 94% of patients reporting
asthma symptoms as better or the same at 3 and
12 months, compared to 71% and 75% at the same
time-points.
Early versus late onset AERD
Nasal inspiratory peak flow (NIPF) increased at 3 m
compared to pre-treatment in those with later onset
AERD (141.6 ± 10.2 L/min pre-treatment and 159.7 ±
9.9 L/min at 3 months, p < 0.05), but not for those with
earlier AERD onset (157.6 ± 16.9 L/min pre-treatment
and 174.7 ± 16.5 L/min at 3 months, p = 0.27).
Smell test scores were significantly higher at both 3 m
and 12 months compared to pre- treatment in thoseTable 1 Subjective changes on lysine aspirin (LAS) treatment
At 3 months
n = 78 n = 78 n = 77 n =
Asthma Rhinitis Nasal polyps Glo
Worse 16 21% 14 18% 24 31% 18
Unchanged 38 49% 43 55% 26 34% 32
Better 24 31% 21 27% 27 35% 28
Better or the same 62 79% 64 82% 53 68% 60with later onset AERD (p < 0.05 at 3 months and p < 0.01
at 12 months), but not for those with earlier AERD onset
(p = 0.30 and 0.50 respectively).
Rhinitis symptom score 24% with later onset disease
noted worsening of rhinitis at 12 months,compared to
60% with early onset.
Anti-leukotriene (LTRA) response and outcomes
Leukotriene receptor antagonists, beneficial in some pa-
tients with asthma and nasal polyposis [6], had been previ-
ously prescribed for 96 patients, of whom 37 found benefit
and continued on treatment. There was no significant dif-
ference in subjective scores and most objective data for
those who found benefit from anti-leukotrienes and those
who did not, with one exception : an increase in NIPF at
3 m in those for whom anti-leukotrienes were not benefi-
cial (145.0 ± 13.8 ppb pre-treatment and 169.2 ± 12.8 ppb
at 3 months, p < 0.05), not present in those on them
(141.3 ± 13.5 ppb pre-treatment and 155.2 ± 13.8 ppb at
3 months, p = 0.34).
Discussion
The patients in this audit are those with AERD refractory
to standard medical and surgical therapy. AERD is a
chronic inflammatory disorder of the respiratory tract [1]
in which despite avoidance of aspirin and NSAIDs, muco-
sal inflammation of the upper and lower respiratory tractsAt 12 months
78 n = 26 n = 26 n = 26 n = 26
bal Asthma Rhinitis Nasal polyps Global
23% 3 12% 8 31% 6 23% 7 27%
41% 10 38% 6 23% 6 23% 4 15%
36% 13 50% 12 46% 14 54% 15 58%
77% 23 88% 18 69% 20 77% 19 73%
Table 2 Objective outcomes on lysine aspirin (LAS)
treatment, –Objective scores pre-treatment and at 3 and
12 months
Pre 3 m 12 m
NIPF (litres/min) 145.4 ± 8.7 163.3 ± 8.5* 160.5 ± 15.9
Expired NO (ppb) 13.2 ± 1.64 14.9 ± 1.63 7.54 ± 0.85* **
Nez du Vin 1.75 ± 0.75 2.54 ± 0.80* 3.13 ± 0.64*
Nasal NO Right (ppb) 336.6 ± 32.7 347.9 ± 34.2 442.23 ± 78.7
Nasal NOLeft (ppb) 343.8 ± 36.7 331.9 ± 39.3 456.4 ± 91.2
*p < 0.05 vs pre treatment.
**p < 0.05 vs 3 m.
***p < 0.05 vs 12 m.
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gressive, a beneficial effect of treatment may be considered
as lack of deterioration as well as improvement of symp-
toms. Based on subjective symptom evaluation the ma-
jority of patients found some benefit from nasal LAS
treatment, a quarter continued regularly with a complex
form of treatment for 12 months, with 73% being globally
improved or stable, meaning that one patient should
benefit in every 5 or 6 who are treated. This compares
favourably with the number needed to treat (NNT) of
4.4 for intranasal corticosteroids, and is superior to the
NNT for antihistamines which is 15.2 ,in allergic rhinitis
treatment [19].
Only 3.8% of 105 patients reported gastro- intestinal
side effects - approximately a quarter of the rate found
with oral aspirin desensitization. There was a high drop
out rate. Lack of any funding for this project meant that
not all patients attended follow up visits, largely because
of expense and time off work. The complexity of making
up a new solution each day then putting it into the nose
in the head upside down position without missing out
more than a day defeated many of the remaining drop
outs, None had any serious adverse event. The number
of subjects known to have left because of side effects of
therapy was nineteen.
However, at 3 and 12 months for all symptom groups
(global, asthma, rhinitis and nasal polyps), there were
some patients whose symptoms were worse than previ-
ously. Our data suggest that those with later onset dis-
ease and positive skin prick tests improve more than
those with onset less than 40 years and negative skin
prick tests. The reasons for this are unknown but could
relate to staphylococcal enterotoxin effects which are
more notable later in the disease course [20].
The effects on asthma were objectively assessed by
comparing lung function tests, and exhaled nitric oxide
levels before treatment and at 3 and 12 months. Exhaled
nitric oxide (eNO),which reflects eosinophilic inflamma-
tion of the lower respiratory tract ,showed significant
changes with an increase at 3 months that could indicate
aspirin–induced mast cell degranulation in the lowerrespiratory tract by aspirin swallowed after nasal inser-
tion, however this was reversed with further treatment
and increased dose of lysine aspirin with a significant de-
crease at 12 months, maintained in patients continued
on LAS therapy (data not shown). The fall in eNO at
12 months and the significantly better asthma outcomes
in those on LAS therapy suggests that treatment mainly
directed at the upper airway also protects the lower.
However there may also be a selection bias, as those in
whom the lower respiratory tract was adversely affected
by LAS, and those who were non-concordant with medi-
cation, would no longer be continuing on treatment. A
double blind, placebo-controlled trial would be ideal, but
difficult because of blinding and funding.
The mechanism of action of LAS used in this way is un-
certain and it is unlikely that patients taking 75 mg nasally
are fully desensitized, though they are tolerating a dose of
aspirin which is optimal for cardiovascular protection [10].
In this respect LAS is likely to be superior to the NSAID
ketorolac, (the only topical form available in the USA)
which is detrimental to the cardiovascular system; and to
oral desensitization, where the higher doses used [7] are
possibly not cardio-protective and are more likely to cause
gastrointestinal bleeding. Our previous work has shown
that cysteinyl LT1receptors are upregulated in AERD in
nasal biopsies [21] and that the percentages of mucosal
CD45 + leukocytes expressing cysteinyl leukotriene LT 1
receptors were significantly (p < 0.0001) elevated in aspirin-
sensitive, but not in aspirin-tolerant patients [22]. In a
small double-blind, placebo- controlled, cross over study
using 16 mg LAS intra-nasally, we found a reduction in
Cys LT1 receptors after 2 weeks, maintained at 6 months,
compared to saline placebo [21].
In an n of 1 study with patients as their own controls
using LAS at 30 mg intra-nasally in addition to routine
therapy, there was significant improvement in polyp
grade and NIPF [23]. Aspirin itself is an anti- inflamma-
tory and this may be relevant, however topical aspirin
was not effective in a double-blind study in aspirin toler-
ant(AT) polyps [24] which makes this simple explanation
unlikely. It is probable that the mechanism of action re-
lates more specifically to aspirin sensitivity and involves
graduated degranulation of mast cells and eosinophils in
the nasal mucosa, plus a reduction in leukotriene recep-
tors, which we have shown previously at lower doses of
intranasal lysine aspirin [21]. In addition lysine itself has
activity against herpes simplex which may be implicated
in AERD pathogenesis [25]. Further double-blind studies
involving mediator release, mucosal genomics, biomics
and proteomics are needed.
Conclusions
This audit shows that for selected patients with refrac-
tory AERD nasal LAS treatment can reduce airway
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sense of smell. Advantages of nasal LAS are a reduced
incidence of gastrointestinal side- effects and a dose
compatible with cardio-protection when compared to
oral desensitization; disadvantages include the need for
daily preparation of the solution and the strict treatment
regime. Since therapy with aspirin, nasally or orally is
inexpensive and relatively safe it should be tried in re-
calcitrant AERD before monoclonal antibodies, such as
anti- IgE or anti-IL5 [26,27].Appendix
Topical lysine aspirin in aspirin exacerbated respiratory
disease
FOLLOWUP QUESTIONNAIRE
1. Name............................................................................
2. Date of birth................................................................
PLEASE CIRCLE THE CORRECT ANSWERS BELOW
3. Gender i) Male ii) Female
4. Are you suffering from asthma? i) Yes ii) No
5. Is your asthma made worse by aspirin? i) Yes ii) No
6. Do you suffer from nasal polyps? i) Yes ii) No
7. Are your nasal polyp -related symptoms made
worse by aspirin? i) Yes ii) No
8. Do you suffer from sneezing or runny nose
(rhinitis)? i) Yes ii) No
9. Does aspirin worsen these symptoms? i) Yes ii) No
10. Have you undergone a lysine aspirin challenge at
RNTNE Hospital? i) Yes ii) No
11. Did you start taking lysine aspirin treatment
following the challenge? i) Yes ii) No
12. Have you stopped taking lysine aspirin treatment
after starting it? i) Yes ii) No
13. If you have stopped; how long had you taken lysine
aspirin for?
14. If you have continued how long have you been
taking lysine aspirin?
15. Medications used before taking lysine aspirin:i) Antihistamines
ii) Nasal steroids
iii) Inhaled steroids
iv)Anti-leukotrienes (montelukast)
v) Oral steroids
16. Medications used after taking lysine aspirin:
i) Antihistamines
ii) Nasal steroids
iii) Inhaled steroids
iv)Anti-leukotrienes (montelukast)
v) Oral steroids
17. How do you rate your symptoms whilst taking
lysine aspirin
i) worse ii) same iii) better?18. Have you suffered from any bad attacks of asthma
in the past year? i) Yes ii) No
19. Have you had extra visits to your GP as a result of
your asthma in the past year?
i) Yes ii) No
20. Have you attended A&E as a result of exacerbation
of your asthma in the past year? i) Yes ii) No
21. Have you received oral steroids (Prednisolone) for
exacerbation of asthma in the past year ? i) Yes ii) No
22. Have you been admitted to hospital and treated as
in-patient for exacerbation of your asthma in the
past year? i) Yes ii) No
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